IBIO - iBio, Inc.
Chart Events
Inside Bar (Bearish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.7781 |
| Open | 0.7935 |
| Bid | 0.7600 x 900 |
| Ask | 0.7682 x 1300 |
| Day's Range | 0.7510 - 0.7997 |
| 52 Week Range | 0.3600 - 16.5000 |
| Volume | |
| Avg. Volume | 602,604 |
| Market Cap | 12.903M |
| Beta (5Y Monthly) | -3.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -148.1700 |
| Earnings Date | May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
Fair Value
Related Research
GlobeNewswireiBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
BRYAN, Texas and SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for immuno-oncology applications. Through comprehensive screening and optimization techniques, iBio has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibod
- GlobeNewswire
iBio to Participate in the JMP Securities Life Sciences Conference
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 12:00 p.m. Eastern Time at the New York Hilton Midtown. The fireside chat will be broadcast live and
- GlobeNewswire
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by its VP & Head of Machine Learning & Platform Technologies, Matt Greving, Ph.D., during Carterra's "Unlocking High-Throughput Biology and Drug Discovery" symposium in San Diego, CA, revealed the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the
- GlobeNewswire
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of the G protein-coupled receptor (“GPCR”) family, is expressed by T-re
- GlobeNewswire
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against cancer - BRYAN, Texas, Feb. 16, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the disclosure of MUC16 as the target of it’s latest immune-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumor
- GlobeNewswire
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
- Machine Learning Model Accelerates Engineering of Polypeptide Therapeutics with Challenging Targets and Mechanisms of Action -BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a ma
- GlobeNewswire
iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of common stock and Series B warrants to purchase up to 3,870,192 shares of common stock, at a combine
- GlobeNewswire
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,365,385 shares of common stock and Series B warrants to purchase up to 3,365,385 shares of common stock, at a combine
- GlobeNewswire
iBio Announces Proposed Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and Series A and Series B warrants to purchase shares of common stock in an underwritten public offering. In connection with the offering, the Company also intends to grant the un
- GlobeNewswire
iBio to Participate in the JMP Securities Hematology and Oncology Summit
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 1:20 p.m. Eastern Time. The fireside chat will be broadcast live and archived on the Company's website at www.ibioinc.com under "
- GlobeNewswire
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California, December 4-8. The AE&T Conference features the latest science and research in antibody engineering, design, and selection to drive commercial advances in fields such as immuno-oncology. iBio will highlig
- GlobeNewswire
iBio Announces CEO Departure
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the “Board”) and Thomas F. Isett, the Company’s Chief Executive Officer, have agreed that Mr. Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the Company, effective immediately. While the Company continues its search for a succes
- GlobeNewswire
iBio Accelerates Transformation to AI-Powered Biotech
– Divesting CDMO business and cGMP biologics manufacturing facility – – Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform – – Restructuring measures to result in ~50% annualized cost savings – BRYAN, Texas and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization (iBio CD
InvestorPlace7 Penny Stocks to Sell Pronto Before a Painful Downturn
It has been a rough year for investors, with the S&P 500 index posting incredible losses not seen in some time. As stocks continue to hover in this fragile market, investors must consider which assets are most valuable in their portfolios. Penny stocks are likely to get the axe, given the massive volatility in the stock market at this time. Most investors are still reticent to invest in penny stocks. Therefore, it’s probably the right time to look at some penny stocks to sell right now. Converse
InvestorPlace3 Healthcare Stocks to Sell Before They Die
The Fed’s key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive. As a result, healthcare companies losing a great deal of money will have trouble obtaining new loans they can afford to pay off, and many such firms will go out of business. For investors, it’s essential to avoid the stocks of such companies, and some readers may even want to consider selling the shares of th
- Thomson Reuters StreetEvents
Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMT
Q4 2022 Ibio Inc Earnings Call
- GlobeNewswire
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. “We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focu
- GlobeNewswire
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company’s transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today a
- GlobeNewswire
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
- Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. The Company recently completed its firs